Dishman Pharmaceuticals & Chemicals Ltd, a Contract Research & Manufacturing Services (CRAM) major, received the US Food and Drug Administration (USFDA) nod for producing Active Pharmaceutical Ingredients (API) at its Naroda facility.

The USFDA team has completed the inspection of Dishman's facility situated at Naroda, in Ahmedabad and has approved the facility for API production for the US market. The Naroda-based facility of Dishman is an Export Oriented Unit (EOU).

The company has recently announced Rs 125 crore capex plan by March end, and also plans to invest another Rs 125-150 crore next year for opening two new API units. It has now begun a restructuring of its subsidiary to boost bottom lines next year.